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S100B, a calcium-binding protein of the EF-hand type, exerts both intracellular and extracellular functions. S100B is induced in
the myocardium of human subjects and an experimental rat model following myocardial infarction. Forced expression of S100B
in neonatal rat myocyte cultures and high level expression of S100B in transgenic mice hearts inhibit cardiac hypertrophy and
the associated phenotype but augments myocyte apoptosis following myocardial infarction. By contrast, knocking out S100B,
augmentshypertrophy,decreasesapoptosisandpreservescardiacfunctionfollowingmyocardialinfarction.ExpressionofS100Bin
aortic smooth muscle cells inhibits cell proliferation and the vascular response to adrenergic stimulation. S100B induces apoptosis
by an extracellular mechanism via interaction with the receptor for advanced glycation end products and activating ERK1/2 and
p53 signaling. The intracellular and extracellular roles of S100B are attractive therapeutic targets for the treatment of both cardiac
and vascular diseases.
1. The Familyof S100 Proteins
S100 proteins entail a multigenic family of calcium binding
proteins of the EF-hand type (helix E-loop-helix F). These
proteins are called S100 because of their solubility in
a 100% -saturated solution with ammonium sulphate at
neutral pH. They are small acidic proteins, 10–12KDa, and
containtwodistinctEF-hands,4α-helicalsegments,acentral
hinge region of variable length, and the N- and C-terminal
variable domains. To date, 25 members of this family have
been identiﬁed [1]. Of these, 21 family members (S100A1-
S100A18, trichohyalin, ﬁlagrin, and repetin) have genes
clustered on a 1.6-Mbp segment of human chromosome
1 (1q21) while other members are found at chromosome
loci 4q16 (S100P), 5q14 (S100Z), 21q22 (S100B), and Xp22
(S100G) [2]. S100 proteins are widely expressed in a variety
of cell types and tissues. For example, S100A1 and S100A2
are found in the cytoplasm and nucleus, respectively, of
smooth-muscle cells of skeletal muscle [3], S100P is located
in the cytoplasm of placental tissue [4, 5], and S100B in
cytoplasm of astrocytes of nervous system [6]. However,
their expression might be repressed in other cell types by
negative regulatory factors which are controlled by envi-
ronmental conditions. For instance induction of S100B in
rat myocardium postinfarction [7] implies that transcription
regulation of these proteins is strongly controlled by negative
and positive elements [8].
S100 proteins do not exhibit intrinsic catalytic activity.
However, they are calcium sensor proteins and through
interaction with several intracellular eﬀector proteins they
contribute to the regulation of a broad range of functions
such as contraction, motility, cell growth and diﬀerentiation,
cell cycle progression, organization of membrane-associated
cytoskeleton elements, cell survival, apoptosis, protein phos-
phorylation, and secretion [1, 3, 9] .I no r d e rt om o d u l a t e
these types of activities, S100 proteins undergo conforma-
tional changes [10]. Upon calcium binding, the helices of
S100proteinsrearrange,revealingahydrophobiccleft,which
forms the target protein binding site [11]. Although target
binding of S100 proteins is calcium-dependent, calcium
independent interactions have been reported [12]. Enzymes
are the most common calcium independent target binding2 Cardiovascular Psychiatry and Neurology
for the S100 proteins. For instance, S100B and S100A1
bind with glycogen phosphorylase [13]. The most signiﬁcant
calcium-independent interactions of S100 proteins are their
ability to bind to each other. Typically, they are homodimers,
but heterodimerization adds to the complexity of this
multiprotein family. Each subunit consists of two helix-
loop-helix motifs connected by a central linker or so-called
hinge region. The C-terminal canonical EF-hand motif is
composed of 12 amino acids, whereas the N-terminal S100-
speciﬁc EF-hand comprises 14 residues [3, 14].
Growing evidence indicates that in addition to intra-
cellular activities, some S100 proteins (e.g., S100B, S100A1,
S100A4,S100A8,andS100A9)exhibitextracellularfunctions
[15]. However, secretion has been shown only for S100B,
S100A8, and S100A9 [15]. The S100A8/A9 heterodimer is
secreted by a novel secretion pathway that depends on
an intact microtubule network and acts as a chemotactic
molecule in inﬂammation [16, 17]. The extracellular eﬀects
of some S100 proteins require binding to the receptor
for advanced glycosylation end products (RAGE) [18–21].
RAGE is a member of the immunoglobulin family of
cell surface molecules recognizing multiple ligands includ-
ing AGE, amphoterin, amyloid-β-peptide and β-ﬁbrils,
S100A12, S100A6, and S100B [22]. The 45-kDa receptor
protein consists of 403 amino acids with an extracellular
domain (1 variable and 2 constant Ig domains with disulﬁde
bridges), a single transmembrane region, and a short cytoso-
lic tail that triggers signal transduction [23]. RAGE ligands
show selective binding to RAGE. S100B tetramer induces
receptor dimerization by binding to RAGE [24]. S100B binds
todomainsVandCIwhereastheRAGEligandS100A6binds
to domains CI and CII [23].
2. Noncardiovascular Actions of S100B
S100B is predominantly expressed in astrocytes, oligo-
dendrocytes, and schwann cells. S100B has intracellular
and extracellular eﬀects [1]. Intracellularly, S100B regulates
the cytoskeletal dynamics through disassembly of tubulin
ﬁlaments, type III intermediate ﬁlaments [1], and bind-
ing to ﬁbrillary proteins such as CapZ [25] or inhibit-
ing GFAP phosphorylation when stimulated by cAMP or
calcium/calmodulin [26]. S100B interacts in a calcium-
dependent manner with the cytoplasmic domain of myelin-
associated glycoprotein and inhibits its phosphorylation by
protein kinase [27]. It is implicated in the phosphorylation
of tau protein [28], inhibition of Ndr kinase activity [29],
inhibition of p53 phosphorylation [30], and regulation of
the activity of the GTPase Rac1 and Cdc eﬀector, IQGAP
[31]. S100B can also be secreted by a number of cell types
(e.g., astrocytes, glial cells) [32]. Astrocytes and glial cells
secrete S100B, by a complex system involving alterations
in intracellular calcium concentration [32]. S100B after
secretion, or simply leakage from damaged cells, could
accumulate in the extracellular space and/or enter the blood
stream and cerebrospinal ﬂuid [33, 34]. The action of S100B
is strongly dependent on its extracellular concentration.































Figure 1: Schematic representation of proposed intracellular and
extracellular eﬀects of S100B in cardiac myocytes. Norepinephrine
(NE) activation of the calcium-dependent protein kinase C (PKC)-
β, mediated by the α1-adrenergic receptor, phosphorylates (P)
transcriptional enhancer factor (1) TEF-1, resulting in DNA
binding and transactivation of the β-myosin heavy chain promoter.
By contrast, S100B induction by NE and other hypertrophic
signals (not shown) results in calcium-dependent block of PKC-β
phosphorylation of TEF-1 and inhibition of β-MHC transcription.
S100Bcanalsoinduceapoptosisintracellularlyviaainduciblenitric
oxide synthase (iNOS)-NO pathway or it can be secreted and via
activation of the receptor for advanced glycation end products
(RAGE)(extracellularcomponentsVandCI),andinduceapoptosis
via MEK-ERK1/2-p53 signaling.
outgrowth; however, at micromolar concentrations it pro-
motes apoptosis [35, 36]. Such high extracellular levels are
detected after brain injury or in neurodegenerative disorders
like Down’s Syndrome, Alzheimer disease, or encephalitis
[37, 38]. Both trophic and toxic eﬀects of extracellular S100B
are mediated in the brain by RAGE [36]. In addition to
playing a major role in brain physiology [1], S100B has
been implicated in cardiovascular development [39] and is
considered a biochemical marker for brain injuries after
bypass graft surgery [40] and dilated cardiomyopathy [41].
3.CardiovascularActions ofS100B
3.1. Intracellular S100B and Myocyte Hypertrophic Gene
Expression. The adult cardiac myocyte is terminally diﬀeren-
tiated and has lost the ability to proliferate. The myocardium
therefore adapts to increasing workloads through hypertro-
phy of individual cells in response to hormonal, paracrine,
and mechanical signals [42, 43]. This process is initially
compensatory but it can progress to irreversible enlargement
and dilatation of the ventricle resulting in heart failure
[44]. Myocyte hypertrophy is accompanied by the down-
regulation of adult α-myosin heavy chain and a program of
fetal gene reexpression including the embryonic β-myosin
heavy chain (MHC), the skeletal isoform of α actin (skACT),
and atrial natriuretic factor (ANF) [45, 46]. This response
can be reproduced in vitro in cultured neonatal cardiac
myocytes by treatment with a number of trophic factors
including peptide growth factors and α1-adrenergic agonistsCardiovascular Psychiatry and Neurology 3
[7]. Negative modulators of the hypertrophic response are
essentialtomaintainabalancebetweencompensatoryhyper-
trophy and unchecked progression. Experimental evidence
suggests that S100B acts as an intrinsic negative regulator
of the myocardial hypertrophic response [47–49]. S100B
not normally expressed in the myocardium, is induced in
the peri-infarct region of the human heart after myocardial
infarction [47] and in rat heart commencing at day 7
following myocardial infarction as a result of experimental
coronary artery ligation [7]. In cultured neonatal rat cardiac
myocytes, transfection of an expression vector encoding the
human S100B protein inhibits the α1-adrenergic induction
of the fetal genes β- MHC and the skACT [7]. The inhibition
of α1-adrenergic induction is selective as S100B does not
inhibit the capacity of thyroid hormone to induce α-myosin
heavy chain. To establish that S100B blocked α1-adrenergic
induction of β -MHC and skACT by interrupting the PKC
signaling pathway, the interaction between forced S100B
expression and a constitutively activated mutant of PKCβ
referred to as δPKCβ was tested [50]. δPKCβ transactivated
the β-MHC and skACT genes supporting the notion that the
α1-adrenergic induction of these genes is mediated by activa-
tion of the class-I PKC isoform β-PKC [7, 50]. Forced S100B
expression could only block δPKCβ-induced transaction of
β-MHC and skACT amidst concomitant treatment with an
α1-adrenergic agonist or augmented extracellular calcium
suggesting that the capacity of S100B to modulate the
hypertrophic phenotype is calcium dependent [7]. The tran-
scription factors TEF-1 (transcription factor-1) and related
TEF-1 (RTEF-1) upon phosphorylation by PKCβ bind to
MCAT elements on the skACT and β-MHC promoters and
activate transcription [51]. In cotransfection experiments,
forced expression of S100B inhibited the activation of the
skACT and β-MHC promoters by overexpression of TEF-
1 (unpublished observations). A direct interaction between
S100B and TEF-1 was demonstrated using a coimmuno-
precipitation strategy (unpublished observations). These
data suggest that S100B modulates the activation of the
fetal genes by direct binding to TEF-1. In addition to
TEF-1, S100B interacts in a calcium-dependent manner
with the giant phosphoprotein AHNAK/desmoyokin in
cardiomyocytes and smooth muscle cells [49]. In cardiomy-
ocytes, AHNAK plays a role in cardiac calcium signaling
by modulating L-type calcium channels in response to β-
adrenergic signaling [52, 53]. The S100B/AHNAK interac-
tion may participate in the S100B-mediated regulation of
cellular calcium homeostasis [53]. Whether there is any
relationship between S100B-mediated eﬀects on calcium
ﬂuxes and S100B-dependent inhibition of the α1-induction
of the hypertrophic phenotype remains to be elucidated.
The function of the S100B/AHNAK interaction in smooth
muscle cells is currently unknown. In the myocardium,
S100B expression is transcriptionally controlled dependent
on positive (−782/−162 and −6,689/−4,463) and negative
(4,463/−782) elements upstream of the transcription initi-
ation site, selectively activated by α1A-adrenergic signaling
via PKCβ and inhibitory and stimulatory DNA binding by
transcription factors, TEF-1 and related RTEF-1, respectively
[8] (Figure 1). This suggests that the same α1-adrenergic
pathwaythatinitiatesandsustainsthehypertrophicresponse
in cardiac myocytes by activating PKC signaling and which
is subject to negative modulation by S100B also induces the
S100B gene.
3.2. Intracellular S100B, Cardiovascular Hypertrophy and
Apoptosis. To provide a physiologic model of S100B overex-
pression eﬀects, transgenic mice were created that contained
multiple copies of the human gene under the control of its
own promoter. These animals demonstrate normal cardiac
structure, and neuronal, but no basal cardiac expression
of the transgene. In S100B transgenic mice, after chronic
α1-adrenergic agonist infusion, S100B is detected in the
heart and increased in the vasculature [49]. In addition,
the myocyte hypertrophy and arterial smooth muscle cell
proliferation normally evoked in the heart and vasculature,
respectively, in response to α1-adrenergic stimulation in
wild-type mice were abrogated in S100B transgenic mice
[49]. In knockout mice, α1-adrenergic agonist infusion
provoked a potentiated myocyte hypertrophic response
and augmented arterial smooth muscle cell proliferation.
Furthermore, in knockout mice, both the acute and chronic
increases in blood pressure in response to α1-adrenergic
agonist infusion were attenuated compared with wild-type
mice [49]. To determine whether this inhibition is general-
izable to other hypertrophic stimuli, transgenic and knock-
out animals were subjected to descending aortic-banding
to produce pressure-overload. Aortic banding for 35 days
increased left ventricular (LV)/body weight (BW) ratio in
CD-1 controls (4.61 ± 0.06g/kg versus 3.44 ± 0.16g/kg
in sham operated, P<. 05, n = 6 )a n dp r o d u c e dn o
hypertrophy in S100B transgenic mice (3.37 ± 0.12g/kg
versus 3.26 ± 0.11g/kg in sham operated, P<. 05, n =
8) and excessive hypertrophy in knock-out mice (5.12 ±
0.24g/kg versus 3.19 ± 0.13g/kg in sham operated, P<
.05, n = 6). Similarly, thirty ﬁve days after experimental
myocardial infarction, the S100B knockout mice mounted
an augmented hypertrophic response compared to wild-
type mice [48]. Fetal gene expression was induced to a
greater magnitude in knockout mice compared to wild-
type mice. The S100B transgenic mice did not develop
the hypertrophic phenotype but demonstrated increased
apoptosis in the peri-infarct region compared to wild-type
and knockout mice. The postinfarct hypertrophic response
in the myocardium is initiated by multiple trophic signals
that include the state of local and systemic sympathetic
hyperactivity through α1-adrenergic stimulation [54]. These
studies in S100B transgenic and knockout mice complement
the culture data and support the hypothesis that S100B acts
both as an intrinsic negative regulator of hypertrophy and
an apoptotic agent. Intracellular S100B may modulate the
apoptotic responses of postinfarct myocytes by activating
a transcriptionally inducible form of nitric oxide synthase
(iNOS)and production of nitric oxide (NO) [55]ashasbee n
described for astrocytes [35]. Forced expression of S100B
may induce iNOS, NO production, and apoptosis. Thus
NO could be an intermediate pathway in the induction of
apoptosisbyintracellularS100B(Figure1).SimilartoS100B,
S100A6 is upregulated in post-infarct myocardium and is4 Cardiovascular Psychiatry and Neurology
selectively induced by TNF-α and serves to limit myocyte
apoptosis [56]. S100B colocalizes with S100A6 in cardiac
muscle [57], suggesting that heterodimerization may have
distinct phenotypic consequences.
3.3. Extracellular S100B and Myocyte Apoptosis. Increasing
evidence suggests that S100B plays a role in the regulation
of apoptosis in post-MI myocardium by an extracellular
mechanism after cellular release from damaged myocytes
and interaction with RAGE [58]. Exogenously administered
S100B to neonatal rat cultures induced apoptosis in a dose-
dependent manner beginning at 0.05μm o l / L ,al o c a lo r
regional concentration that may be achieved in the peri-
infarct myocardium [48]. Similarly, S100B at dose ≥0.05
μmol/L induced neuronal cell death [59]. Myocyte apoptosis
is accompanied by cytochrome C release from mytochondria
to cytoplasm, increased expression and activity of pro-
apoptotic caspase-3, decreased expression of anti-apoptotic
Bcl-2, and phosphorylation of ERK1/2 and p53 [58, 60,
61] (Figure 1). Transfection of a full-length cDNA of
RAGE or a dominant-negative mutant of RAGE resulted in
increased or attenuated S100B-induced myocyte apoptosis,
respectively, implicating RAGE dependence. Inhibition of
MEK signaling or overexpression of a dominant negative
p53 inhibits S100B-induced myocyte apoptosis. This implies
that RAGE activation by S100B increases MEK MAPK
kinase signaling, p53 phosphorylation at serine 15, and p53-
dependent myocyte apoptosis (Figure 1).
The eﬀects of S100B on myocyte apoptosis stand in con-
trast to S100A1, the most abundant S100 protein expressed
in cardiac muscle under basal conditions [62]. S100A1
exhibits increased expression in compensated hypertrophy,
decreased expression in human cardiomyopathy, and down-
regulationfollowingexperimentalmyocardialinfarction[63,
64]. S100A1 knockout mice showed elevated systemic blood
pressure, reduced endothelium-dependent vasorelaxation,
and decreased survival after myocardial infarction [65, 66].
Like our proposed mechanism for S100B release, S100A1
is released into the extracellular space in the setting of
myocardial injury and can bind RAGE [58]. Unlike S100B,
extracellular S100A1 inhibits apoptosis independent of
RAGE [67] or by RAGE signaling by interacting with a
diﬀerent extracellular domain of RAGE as has been shown
with other RAGE ligands [23]. Thus, S100 proteins may
diﬀerentially regulate myocardial structure and function.
Given the capacity of S100A1 and S100B to heterodimerize,
phenotypic consequences may depend on the availability
and stoichiometry of S100A1 and S100B homodimers and
heterodimers.
4. Concluding Remarks
In conclusion, the S100 family constitutes the largest sub-
group of the EF-hand family of calcium-binding proteins
with 25 members. S100 proteins have been implicated in
pleiotropic calcium-dependent cellular events, with speciﬁc
functions for each of the family members. S100B is induced
inperi-infarctmyocytespostmyocardialinfarctioninhuman
subjects and experimental rodent models of myocardial
infarction and in response to α1-adrenergic stimulation.
S100B plays an important role in negative intrinsic regu-
lation of aortic smooth muscle cell proliferation, cardiac
myocytehypertrophy,and,viaRAGEligation,apoptosis.The
intracellular and extracellular roles of S100B are attractive
therapeutic targets for the treatment of both cardiac and
vascular diseases.
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